The Experts below are selected from a list of 13536 Experts worldwide ranked by ideXlab platform
Byungjoo Lee - One of the best experts on this subject based on the ideXlab platform.
-
tumor location dependent skip lateral cervical lymph node metastasis in Papillary Thyroid Cancer
Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2014Co-Authors: Jinchoon Lee, Soogeun Wang, Yunsung Lim, Yoonse Lee, Inju Kim, Seokman Son, Sungchan Shin, Byungjoo LeeAbstract:Background Lateral cervical lymph node metastasis without central lymph node (CLN) metastasis is not infrequent in Papillary Thyroid Cancer (PTC). This study was designed to investigate the frequency and pattern of skip metastasis in PTC. Methods We reviewed 131 patients who underwent total Thyroidectomy with CLN dissection and selective lymph node dissection. Tumor location was classified in 3 areas (upper, middle, and lower third) based on preoperative ultrasonographic findings. Results All skip metastases occurred in patients whose tumors had been on the upper part of the Thyroid (p < .001). Among 9 patients with skip metastasis, level III lymph nodes (66.7%) were the lymph nodes that were most frequently involved in skip metastasis. Conclusion Primary tumors in the upper portion of the Thyroid are closely linked to skip metastasis. Careful preoperative evaluation of lateral cervical lymph nodes is suggested when a tumor is in the upper portion. © 2013 Wiley Periodicals, Inc. Head Neck 36: 887–891, 2014
-
cln metastasis with Papillary Thyroid Cancer in the isthmus
Otolaryngology-Head and Neck Surgery, 2012Co-Authors: Jinchoon Lee, Byungjoo Lee, Soogeun Wang, Yunsung Lim, Yoonse LeeAbstract:Objective: To investigate the patterns and predictive factors of central lymph node metastasis in patients with Papillary Thyroid Cancer located in the isthmus.Method: Retrospective chart review. We evaluated 447 cases with solitary nodule out of 1257 patients with Papillary Thyroid Cancer who underwent total Thyroidectomy with bilateral central lymph node compartment dissection. The patients were analyzed in 2 groups: group I, patients with Cancer located in the isthmus (n = 35) and group II, patients with Cancer in other regions (n = 412). We evaluated the clinicopathological characteristics and predictive factors and compared the 2 groups.Results: The frequency of central lymph node(CLN) involvement was 52.1% (233 cases) in the patients with single nodule of Papillary Thyroid Cancer. The frequency of Papillary Thyroid Cancer located in the isthmus was 7.8% (35 cases). Mean age at diagnosis in group I and II was 45.3 years and 46.2 years, respectively (P = .892). Size, sex, extraThyroidal extension, and...
-
metastasis of right upper para esophageal lymph nodes in central compartment lymph node dissection of Papillary Thyroid Cancer
World Journal of Surgery, 2009Co-Authors: Byungjoo Lee, Jinchoon Lee, Soogeun Wang, Yong Ki Kim, Inju Kim, Seokman SonAbstract:Background Although some lymph nodes (upper para-esophageal lymph nodes) that exist between the right recurrent laryngeal nerve and the esophagus should be involved in central-compartment lymph node dissection (CLND) in patients with Papillary Thyroid Cancer, the procedure can cause some injury to the nerve. We set out to assess the incidence of right upper para-esophageal lymph node metastasis after routine CLND.
Francesco Vermiglio - One of the best experts on this subject based on the ideXlab platform.
-
Papillary Thyroid Cancer incidence in the volcanic area of sicily
Journal of the National Cancer Institute, 2009Co-Authors: Gabriella Pellegriti, Marco Attard, Claudia Scollo, S. Arena, Gabriella Dardanoni, Florent De Vathaire, Pasqualino Malandrino, Francesco Frasca, Carla Giordano, Francesco VermiglioAbstract:Background The steadily increasing incidence of Thyroid Cancer has been attributed mostly to more sensitive Thyroid nodule screening. However, various environmental factors, such as those associated with volcanic areas, cannot be excluded as risk factors. We evaluated Thyroid Cancer incidence in Sicily, which has a homogenous population and a province (Catania) that includes the Mt Etna volcanic area. Methods In a register-based epidemiological survey, we collected all incident Thyroid Cancers in Sicily from January 1, 2002, through December 31, 2004. The age-standardized incidence rate for the world population (ASR(w)) was calculated and expressed as the number of Thyroid Cancer diagnoses per 100 000 residents per year. The association of Thyroid Cancer incidence rate with sex, age, tumor histotype, and various environmental factors was evaluated by modeling the variation of the ASR(w). All statistical tests were two-sided. Results In 2002-2004, 1950 incident Thyroid Cancers were identified in Sicily (among women, ASR(w) = 17.8, 95% confidence interval [CI] = 16.9 to 18.7; and among men, ASR(w) = 3.7, 95% CI = 3.3 to 4.1). Although the percentage of Thyroid Cancers that were microcarcinomas (ie, Conclusion Residents of Catania province with its volcanic region appear to have a higher incidence of Papillary Thyroid Cancer than elsewhere in Sicily.
-
Papillary Thyroid Cancer incidence in the volcanic area of sicily
Journal of the National Cancer Institute, 2009Co-Authors: Gabriella Pellegriti, Marco Attard, Claudia Scollo, S. Arena, Gabriella Dardanoni, Florent De Vathaire, Pasqualino Malandrino, Francesco Frasca, Carla Giordano, Francesco VermiglioAbstract:Background The steadily increasing incidence of Thyroid Cancer has been attributed mostly to more sensitive Thyroid nodule screening. However, various environmental factors, such as those associated with volcanic areas, cannot be excluded as risk factors. We evaluated Thyroid Cancer incidence in Sicily, which has a homogenous population and a province (Catania) that includes the Mt Etna volcanic area. Methods In a register-based epidemiological survey, we collected all incident Thyroid Cancers in Sicily from January 1, 2002, through December 31, 2004. The age-standardized incidence rate for the world population (ASR(w)) was calculated and expressed as the number of Thyroid Cancer diagnoses per 100 000 residents per year. The association of Thyroid Cancer incidence rate with sex, age, tumor histotype, and various environmental factors was evaluated by modeling the variation of the ASR(w). All statistical tests were two-sided. Results In 2002-2004, 1950 incident Thyroid Cancers were identified in Sicily (among women, ASR(w) = 17.8, 95% confidence interval [CI] = 16.9 to 18.7; and among men, ASR(w) = 3.7, 95% CI = 3.3 to 4.1). Although the percentage of Thyroid Cancers that were microcarcinomas (ie, Conclusion Residents of Catania province with its volcanic region appear to have a higher incidence of Papillary Thyroid Cancer than elsewhere in Sicily.
Colleen M Lennard - One of the best experts on this subject based on the ideXlab platform.
-
intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease free survival in Papillary Thyroid Cancer
Surgery, 2001Co-Authors: Colleen M Lennard, Aneeta Patel, John W Wilson, Brian ReinhardtAbstract:Abstract Background. Vascular endothelial growth factor (VEGF) induces proliferation of endothelial cells, stimulates angiogenesis, and increases vascular permeability. Increased VEGF expression has been associated with poor clinical outcomes in many malignancies. Several recent reports have documented over expression of VEGF in Papillary Thyroid Cancer. We hypothesized that increased expression of VEGF would be associated with either an increased risk of recurrence or a decreased recurrence-free survival in Papillary Thyroid Cancer. Methods. Immunohistochemistry was used to detect VEGF expression in archival paraffin-embedded surgical Thyroid specimens from 96 subjects with Papillary Thyroid Cancer. Results. VEGF expression was detected in 98% (94/96) of the samples, predominantly of slight-to-moderate intensity in the majority of malignant cells. However, the specific finding of a diffuse pattern of intense immunostaining for VEGF was detected significantly more often than less intense, patchy immunostaining patterns in subjects with distant metastasis at diagnosis (63% versus 15%, P =.005), local recurrence (58% versus 13%, P =.001), and distant recurrence (83% versus 14%, P =.001). Furthermore, this specific pattern of diffuse, intense VEGF expression was associated with a significantly shorter recurrence-free survival than other staining patterns ( P =.007). Conclusions. These data demonstrate that the immunohistochemical pattern of VEGF staining in the initial surgical specimen is strongly associated with the incidence of local and distant metastasis in Papillary Thyroid Cancer. (Surgery 2001;129:552-8.)
Mingzhao Xing - One of the best experts on this subject based on the ideXlab platform.
-
association between braf v600e mutation and recurrence of Papillary Thyroid Cancer
Journal of Clinical Oncology, 2015Co-Authors: Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina MianAbstract:Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of Papillary Thyroid Cancer (PTC). Patients and Methods This was a retrospective multicenter study of the relat...
-
association between braf v600e mutation and recurrence of Papillary Thyroid Cancer
Journal of Clinical Oncology, 2015Co-Authors: Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina MianAbstract:Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of Papillary Thyroid Cancer (PTC). Patients and Methods This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months). Results The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAF V600E mutation–positive and 11.6% (125 of 1,082) of BRAF V600E mutation–negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation–positive versus –negative patients (P < .001), with a hazard ratio (HR) of 1.82 (95% CI, 1.46 to 2.28), which remained significant in a multivariable model adjusting for patient sex and age at diagnosis, medical center, and ...
-
prognostic utility of braf mutation in Papillary Thyroid Cancer
Molecular and Cellular Endocrinology, 2010Co-Authors: Mingzhao XingAbstract:Papillary Thyroid Cancer (PTC) is a common endocrine malignancy that frequently harbors the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this mutation has received considerable attention in recent years for its potential utility in the risk stratification and management of PTC. In PTC, BRAF mutation is closely associated with extraThyroidal extension, lymph node metastasis, advanced tumor stages, disease recurrence, and even patient mortality. Many of the responsible molecular derangements promoted by, or associated with, BRAF mutation have been identified, including over-expression of tumor-promoting genes, suppression of tumor-suppressor genes, and silencing of Thyroid iodide-handling genes, resulting in impairment or loss of radioiodine avidity and hence the failure of radioiodine treatment of PTC. BRAF mutation can be readily tested on Thyroid fine needle aspiration biopsy specimens, with high preoperative predictive probabilities for clinicopathological outcomes of PTC. As such, the knowledge of BRAF mutation status can facilitate more accurate risk stratification and better decision making at various steps in the management of PTC, from preoperative planning of initial surgical scale to postoperative decisions about appropriate radioiodine treatment and Thyroid-stimulating hormone suppression, and to selections of appropriate surveillance modalities for PTC recurrence. The greatest utility of BRAF mutation status is in those cases where traditional clinicopathological criteria alone would otherwise be unreliable in the risk stratification and management of PTC. Use of this unique molecular marker, in conjunction with conventional clinicopathological risk factors, to assist the prognostication of PTC is likely to improve the efficiency of contemporary management of Thyroid Cancer.
-
braf mutation in Papillary Thyroid Cancer pathogenic role molecular bases and clinical implications
Endocrine Reviews, 2007Co-Authors: Mingzhao XingAbstract:In recent years, the T1799A B-type Raf kinase (BRAF) mutation in Thyroid Cancer has received enthusiastic investigation, and significant progress has been made toward understanding its tumorigenic role and clinical significance. Among various Thyroid tumors, this mutation occurs uniquely in Papillary Thyroid Cancer (PTC), the most common endocrine malignancy, and some apparently PTC-derived anaplastic Thyroid Cancers. Many studies have found this mutation to be associated with those clinicopathological characteristics of PTC that are conventionally known to predict tumor progression and recurrence, including, for example, old patient age, extraThyroidal invasion, lymph node metastasis, and advanced tumor stages. Direct association of BRAF mutation with the clinical progression, recurrence, and treatment failure of PTC has also been demonstrated. The BRAF mutation has even been correlated with PTC recurrence in patients with conventionally low-risk clinicopathological factors. Some molecular mechanisms det...
-
braf mutation predicts a poorer clinical prognosis for Papillary Thyroid Cancer
The Journal of Clinical Endocrinology and Metabolism, 2005Co-Authors: Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohe, Eli Rosenbaum, Kerry J Rhode, Kathry A Carso, Vasily Vasko, A Lari, Giovanni TalliniAbstract:Context: Use of BRAF mutation in Papillary Thyroid Cancer (PTC) has the potential to improve risk stratification of this Cancer. Objective: The objective of the study was to investigate the prognostic value of BRAF mutation in patients with PTC. Design, Setting, and Subjects: In a multicenter study of 219 PTC patients, data on their clinicopathological characteristics and clinical courses between 1990 and 2004 were retrospectively collected, and their tumor BRAF mutation status was determined. Associations of BRAF mutation with initial tumor characteristics and subsequent recurrence were analyzed. Main Outcome Measure: Relationships between the BRAF mutation status and clinicopathological outcomes, including recurrence, were measured. Results: We found a significant association between BRAF mutation and extraThyroidal invasion (P < 0.001), lymph node metastasis (P < 0.001), and advanced tumor stage III/IV (P = 0.007) at initial surgery. This association remained significant on multivariate analysis, adjus...
Gabriella Pellegriti - One of the best experts on this subject based on the ideXlab platform.
-
lymph node location is a risk factor for Papillary Thyroid Cancer related death
Journal of Endocrinological Investigation, 2018Co-Authors: Giulia Sapuppo, Pasqualino Malandrino, Martina Tavarelli, Marco Russo, A Belfiore, Riccardo Vigneri, Gabriella PellegritiAbstract:Papillary Thyroid Cancer (PTC) has good prognosis with a very low chance of mortality. The prognostic role of metastatic lymph node location was judged controversial and more recently (TNM VIII ed.) was considered to have no impact on the prognosis of older patients. The aim of the study was to evaluate the role of metastasized node location on PTC-related mortality. PTC-related mortality was analysed in a consecutive retrospective series of 1653 PTC patients followed at our Thyroid Clinic (mean follow-up 5.9 years). Sixteen out of 1653 patients (0.96%) died because of PTC. Average age was 68 years at presentation and 74.7 at death. F/M ratio was 1:1. The death rate increased in relation to the lymph node status: 0.2% in N0, 0.3% in N1a and 3.0% in N1b. The presence of lymph node metastases in the N1b compartment should be considered as a risk factor for distant metastatic spread and for Cancer-related death and included in post-surgery evaluation.
-
Papillary Thyroid Cancer incidence in the volcanic area of sicily
Journal of the National Cancer Institute, 2009Co-Authors: Gabriella Pellegriti, Marco Attard, Claudia Scollo, S. Arena, Gabriella Dardanoni, Florent De Vathaire, Pasqualino Malandrino, Francesco Frasca, Carla Giordano, Francesco VermiglioAbstract:Background The steadily increasing incidence of Thyroid Cancer has been attributed mostly to more sensitive Thyroid nodule screening. However, various environmental factors, such as those associated with volcanic areas, cannot be excluded as risk factors. We evaluated Thyroid Cancer incidence in Sicily, which has a homogenous population and a province (Catania) that includes the Mt Etna volcanic area. Methods In a register-based epidemiological survey, we collected all incident Thyroid Cancers in Sicily from January 1, 2002, through December 31, 2004. The age-standardized incidence rate for the world population (ASR(w)) was calculated and expressed as the number of Thyroid Cancer diagnoses per 100 000 residents per year. The association of Thyroid Cancer incidence rate with sex, age, tumor histotype, and various environmental factors was evaluated by modeling the variation of the ASR(w). All statistical tests were two-sided. Results In 2002-2004, 1950 incident Thyroid Cancers were identified in Sicily (among women, ASR(w) = 17.8, 95% confidence interval [CI] = 16.9 to 18.7; and among men, ASR(w) = 3.7, 95% CI = 3.3 to 4.1). Although the percentage of Thyroid Cancers that were microcarcinomas (ie, Conclusion Residents of Catania province with its volcanic region appear to have a higher incidence of Papillary Thyroid Cancer than elsewhere in Sicily.
-
Papillary Thyroid Cancer incidence in the volcanic area of sicily
Journal of the National Cancer Institute, 2009Co-Authors: Gabriella Pellegriti, Marco Attard, Claudia Scollo, S. Arena, Gabriella Dardanoni, Florent De Vathaire, Pasqualino Malandrino, Francesco Frasca, Carla Giordano, Francesco VermiglioAbstract:Background The steadily increasing incidence of Thyroid Cancer has been attributed mostly to more sensitive Thyroid nodule screening. However, various environmental factors, such as those associated with volcanic areas, cannot be excluded as risk factors. We evaluated Thyroid Cancer incidence in Sicily, which has a homogenous population and a province (Catania) that includes the Mt Etna volcanic area. Methods In a register-based epidemiological survey, we collected all incident Thyroid Cancers in Sicily from January 1, 2002, through December 31, 2004. The age-standardized incidence rate for the world population (ASR(w)) was calculated and expressed as the number of Thyroid Cancer diagnoses per 100 000 residents per year. The association of Thyroid Cancer incidence rate with sex, age, tumor histotype, and various environmental factors was evaluated by modeling the variation of the ASR(w). All statistical tests were two-sided. Results In 2002-2004, 1950 incident Thyroid Cancers were identified in Sicily (among women, ASR(w) = 17.8, 95% confidence interval [CI] = 16.9 to 18.7; and among men, ASR(w) = 3.7, 95% CI = 3.3 to 4.1). Although the percentage of Thyroid Cancers that were microcarcinomas (ie, Conclusion Residents of Catania province with its volcanic region appear to have a higher incidence of Papillary Thyroid Cancer than elsewhere in Sicily.
